FDA Peptide Update: Category 2 Removals Explained FDA Evaluates Peptides for Section 503A Compounding List Lance Liberti, MBA, BCPA posted on the topic LinkedIn FDA Removes 12 Peptides from 503A Category 2 : r us_pharmacies FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of Understanding the Legal Risks of BPC 157 and Other Unapproved Peptides Holt Law